AbbVie Inc (ABBV) : Icon Advisers Incco scooped up 1,700 additional shares in AbbVie Inc during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 9, 2016. The investment management firm now holds a total of 217,800 shares of AbbVie Inc which is valued at $14,581,710.AbbVie Inc makes up approximately 0.96% of Icon Advisers Incco’s portfolio.
Other Hedge Funds, Including , Taylor Cottrill Erickson Associates reduced its stake in ABBV by selling 1,224 shares or 2.77% in the most recent quarter. The Hedge Fund company now holds 43,006 shares of ABBV which is valued at $2,879,252. AbbVie Inc makes up approx 0.79% of Taylor Cottrill Erickson Associates’s portfolio.Wealthsource Partners reduced its stake in ABBV by selling 4,867 shares or 53.08% in the most recent quarter. The Hedge Fund company now holds 4,303 shares of ABBV which is valued at $288,086. AbbVie Inc makes up approx 0.10% of Wealthsource Partners’s portfolio.Bennicas Associates reduced its stake in ABBV by selling 600 shares or 3.04% in the most recent quarter. The Hedge Fund company now holds 19,110 shares of ABBV which is valued at $1,211,765. AbbVie Inc makes up approx 1.07% of Bennicas Associates’s portfolio.First Hawaiian Bank reduced its stake in ABBV by selling 458 shares or 3.65% in the most recent quarter. The Hedge Fund company now holds 12,082 shares of ABBV which is valued at $782,551. AbbVie Inc makes up approx 0.13% of First Hawaiian Bank’s portfolio.
AbbVie Inc opened for trading at $66.69 and hit $67.35 on the upside on Wednesday, eventually ending the session at $66.83, with a gain of 0.13% or 0.09 points. The heightened volatility saw the trading volume jump to 79,45,418 shares. Company has a market cap of $108,835 M.
On the company’s financial health, AbbVie Inc reported $1.26 EPS for the quarter, beating the analyst consensus estimate by $ 0.06 according to the earnings call on Jul 29, 2016. Analyst had a consensus of $1.20. The company had revenue of $6452.00 million for the quarter, compared to analysts expectations of $6207.43 million. The company’s revenue was up 17.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.08 EPS.
Many Wall Street Analysts have commented on AbbVie Inc. AbbVie Inc was Downgraded by Morgan Stanley to ” Equal-Weight” on Jun 8, 2016.
AbbVie Inc. (AbbVie) is a global research-based biopharmaceutical company. The Company develops and markets therapies that address a range of diseases. The Company’s products are focused on treating conditions such as chronic autoimmune diseases including rheumatoid arthritis psoriasis and Crohn’s disease; hepatitis C (HCV); human immunodeficiency virus (HIV); endometriosis; thyroid disease; Parkinson’s disease; complications associated with chronic kidney disease and cystic fibrosis and other health conditions such as low testosterone. AbbVie also has a pipeline of new medicines including over 30 compounds or indications in Phase II or Phase III development across a range of medical specialties such as immunology virology/liver disease oncology renal disease neurological diseases and women’s health. The Company’s product portfolio includes HUMIRA HCV products Additional Virology products Metabolics/Hormones products Endocrinology products and other products.